Biological Information

Background Information:

There are three known subtypes of b-adrenergic receptors, b1, b2, and b3, all of which are thought to couple primarily via Gsa to adenylyl cylase, leading to an increase in cAMP. The receptor subtypes differ primarily in their location: b1-adrenoceptors predominate in the heart, cerebral cortex, and the kidney. The major subtype in the lungs, cerebellum, uterus, skeletal muscle, and blood vessels is the b2-adrenoceptor. The b3-adrenoceptor has been detected in brain, stomach, and gall bladder but are expressed predominantly in white and brown adipose tissue (WAT and BAT, respectively). b2 adrenoceptors are mainly associated with causing relaxation of smooth muscle in a variety of tissues. Adrenergic b2 receptor agonism have been found useful in the treatment of bronchospasm but may facilitate cardiac arrest. Adrenergic b2 receptor antagonism may facilitate bronchospasm and impair exercise stress cardiovascular performance.

No. of Assays on Panel:

2

Assays on Panel:

Family

GPCR

Name

Item

1976

Protein

beta2

Organism

Human

Assay Sub Type

Cell Based

Family

GPCR

Name

Item

1977

Protein

beta2

Organism

Human

Assay Sub Type

Cell Based

Family:

GPCR

Sub Family:

Adrenoceptor

Class:

Class A

Protein Name:

beta2

Uniprot Number:

P07550

Protein Aliases:

Beta-2 adrenoceptor

Gene Name:

ADRB2

Gene ID:

154

Gene Aliases:

ADRBR|BAR|B2AR

Organism:

Human

Cell Type:

CHO-K1

Assay Information

Assay Type:

Functional

Assay Sub Type:

Cell Based

Functional Mode:

Agonist & Antagonist

Detection Method:

HTRF

Testing Information

Incubation:

30 min at RT

Control Activator:

isoproterenol (10 nM)

Test Concentration / Dose:

Eurofins will provide IC/EC50 calculation if 5 or more concentrations are selected.

Test Sample Requirements:

Minimum for 1) Screen: 60 µL of 10 mM stock -OR- 1 mg (pre-weighed) for 10µM finµL testing. 2) Dose Response: 90 µL of 10 mM stock -OR- 1 mg (pre-weighed) for a top concentration at 10 µM.

Minimum Order Quantity:

16

Turnaround Time

Standard:

15 Business Days

Clinical Relevance

Therapeutic Area:

Pulmonology

Adverse / Beneficial Action:

Adrenergic b2 receptor agonism have been found useful in the treatment of bronchospasm but may facilitate cardiac arrest. Adrenergic b2 receptor antagonism may facilitate bronchospasm and impair exercise stress cardiovascular performance.

Additional Information

Brand:

LeadHunter

Testing Location:

France - Celle L'Evescault

RELATED SOLUTIONS

Item: 20
Item: 1976
Item: 1977